Alzheimer's Disease Drug Market is Declining and it is Expected to fall till 2016

News provided by

Dec 09, 2013, 10:30 ET

MUMBAI, India, December 9, 2013 /PRNewswire/ --

Bharat Book Bureau presents Alzheimer's Pipeline Drugs Review, Alzheimer's disease Drug Market & Forecast - Global Analysis. This report Alzheimer's disease drug market is on the curvature stage. Since 2003, there is not any single "magic bullet" launched in the market to prevent or cure it. However, all current marketed products are going to be generic in the next 3-4 years. There are high unmet medical needs. The current unmet needs represent a huge opportunity for pharmaceutical companies which are developing targeted novel therapies. If successful, they will be in a position to command premium prices and tap the existing opportunity. Lot of drugs has failed in Phase III stage thus putting a greater impact on Alzheimer's disease drug market. (http://www.bharatbook.com/healthcare-market-research-reports/alzheimers-pipeline-drugs-review-alzheimers-disease-drug-market-forecast-global-analysis.html)

(Logo: http://photos.prnewswire.com/prnh/20130128/590935 )

From the year 2009 Alzheimer's disease drug market is declining and it is expected to fall till 2016. But with the expected launch of some Alzheimer's drugs from the year 2017 onwards, Alzheimer's disease drug market is expected to revive in the coming years. However due to absence of exact potential drugs there will always remain a huge Unmet Alzheimer's Drug Market. For the year 2018 Alzheimer's disease Drug Market will be just 10% of Unmet Alzheimer's Disease Drug Market.

"Alzheimer's Pipeline Drugs Review, Alzheimer's Disease Drug Market & Forecast - Global Analysis" provides a comprehensive assessment of the fast-evolving, high-growth Global Alzheimer's Disease Market. This 110 page report with 29 Figures and 11 Tables studies the Global Alzheimer's Disease Drug Market.

Present & Pipeline Drugs Studied in this Report

Namenda
Ebixa
Axura
Aricept
Nootropil
Exelon
Memary
Solanezumab
LuAe58054

This report contains 10 chapters.

Chapter 1: Executive Summary

Chapter 2: This Chapter is divided into 2 parts

Alzheimer's Disease Drug Market & Forecast data available from 2003 to 2018
Unmet Alzheimer's Disease Drug Market & Forecast (Market Potential) data available from 2010 to 2018. (Unmet market is the potential market which could have been achieved if right drug have been introduced in the market)

Chapter 3: This chapter talks about drugs which has failed while in Clinical trials

Chapter 4: This chapter provides Market Share of Alzheimer's Disease Drug from 2003 to 2018. All the 9 Alzheimer's drug mentioned above have been covered in this chapter.

Chapter 5: This chapter talks about Alzheimer's Drugs performance. All important drugs mentioned above past, present & future market data available from 2003 to 2018.

Chapter 6: Pipeline drugs (Solanezumab, LuAE58054, Gantenerumab, Crenezumab, TRx0237 (LMTX), MK-8931, ABT-126, and AZD-1446) have been analyzed in this chapter. All drugs have been analyzed from 5 view points:

Clinical Development Stage
Pipeline Drug Sales Performance
Recent Clinical Development
Different Companies Deal
Investment

Chapter 7: This chapter speaks of Alzheimer's Drugs Company deals in four areas

Strategic Alliances in Alzheimer's Disease Drug Market
Licensing Agreement in Alzheimer's Disease Drug Market
Collaboration Deal in Alzheimer's Disease Drug Market
Merger & Acquisition in Alzheimer's Disease Drug Market

Chapter 8: This chapter studies Funding in Alzheimer's disease Drugs Research. We have covered 5 institutes which provides fund for the research.

Chapter 9: This chapter studies Growth Factors Driving the Alzheimer's disease Drug Market.

Chapter 10: This chapter studies Challenges/Hindrances faced by Alzheimer's disease Drug Market.

Table of Contents

Executive Summary

Worldwide - Alzheimer's Disease Drug Market Analysis

Alzheimer's Disease Drug Market & Forecast
Unmet Alzheimer's Disease Drug Market & Forecast (Market Potential)

Failed Alzheimer's Drugs

Dismal Results but Still Trying Again

Worldwide - Alzheimer's Disease Drug Market Share & Forecast

Worldwide - Alzheimer's Drug Brands Market Performance
Exelon (Rivastigmine) - Past, Present & Future Market
Aricept (Donepezil) - Past, Present & Future Market
Memantine (Namenda, Ebixa, Axura, Memary) Past, Present & Future Market
Namenda (Memantine) - Past, Present & Future Market
Ebixa (Memantine) - Past, Present & Future Market
Axura (Memantine) - Past, Present & Future Market
Memary (Memantine) - Past, Present & Future Market
Nootropil (Piracetam) - Past, Present & Future Market

Pipeline Drugs Analysis in Alzheimer's disease Market

Solanezumab (LY2062430) - Eli Lilly
Clinical Development Stage
Phase - II
Phase - III
Solanezumab Drug Sales (2017 - 2020)
Recent Clinical Development

LuAE58054 - Lundbeck

Clinical Development Stage
Phase - II
LuAE58054 Drug Sales (2017 - 2018)
Deal on LuAE58054

Gantenerumab - Roche

Clinical Development Stage
Phase - I
Phase - II & III
Phase - III
Investment in Gantenerumab Drug

Crenezumab - Genentech

Clinical Development Stage
Phase - II
Investment in Crenezumab Drug

TRx0237 (LMTX) - TauRx Therapeutics Ltd.

Clinical Development Stage
Phase - II
Phase - III
Investment in TRx0237 (LMTX) Drug

MK-8931 - Merck

Clinical Development Stage
Phase - II/III

ABT-126 - AbbVie

Clinical Development Stage
Phase - I
Phase - II

AZD-1446 - Targacept/AstraZeneca

Clinical Development Stage
Phase - I
Recent Development

M&A, Licensing Agreement, Strategic Alliances & Collaboration Deals in Alzheimer's disease Drug Market

Strategic Alliances in Alzheimer's Disease Drug Market
Licensing Agreement in Alzheimer's Disease Drug Market
Collaboration Deal in Alzheimer's Disease Drug Market
Merger & Acquisition in Alzheimer's Disease Drug Market

Funding in Alzheimer's disease Drugs Research

National Institute of Health
Alzheimer's Association
Cure Alzheimer's Fund
Alzheimer's Drug Discovery Foundation
Bright Focus Foundation [formerly American Health Assistance Foundation (AHAF)]

Key Drivers of Growth in Global Alzheimer's disease Drug Market

Aging Population
Global Ageing Indicators
Population Aged 60 or Over: World and Development Regions, 1950 - 2050
Worldwide - Distribution of Population Aged 60 Years or Over By Broad Age Group, 1950 - 2050
Unmet Medical Needs
The Launches of New Drugs Solanezumab, LuAE58054, Gantenerumab & TRx0237 Will Boost the Alzheimer's Market Through 2018
Future Drugs for Disease Modification in Alzheimer's Disease

Key Challenges in the Global Alzheimer's disease Drug Market

Lack of Validated Targets & Lack of Animal Models
Barriers in the Design and Implementation of Clinical Trials
Barriers in Academia & Regulatory Issues
Alzheimer's Drug Failure: Insinuation for Future R&D in Neuroscience
Costly Alzheimer's Drug Development Dissuade Drug Companies
Research Setbacks and Stepping Stones

Request for sample pages: http://www.bharatbook.com/RequestSample.asp?pid=199411

For more information on the report: http://www.bharatbook.com/healthcare-market-research-reports/alzheimers-pipeline-drugs-review-alzheimers-disease-drug-market-forecast-global-analysis.html

Related Reports:

Related Category:

About Bharat Book Bureau

Bharat Book Bureau is the leading market research information aggregator that provides market research reports, industry analysis, company profiles, business reports, country reports, newsletters and online databases. Our clients include Corporate, Consulting firms, and Academic Institutions and Government departments across the globe. Bharat Book Bureau provides over a million reports from more than 400 publishers around the globe. The market research reports we provide, help global companies examine the different markets before setting up a business or expanding into different countries across the world. They give a complete perspective on the current market scenario, trends, segments and future outlook.

Contact us:
Poonam
Bharat Book Bureau
USA/Canada - 1-866-279-8368 (Toll free)
India: +91-22-27810772, 27810773
Blog: http://blog.bharatbook.com
E: [email protected]
W: http://www.bharatbook.com

SOURCE Bharat Book Bureau